Join IAG’s Bio-Partnering at HC Wainwright 2020

Join IAG's Bio-Partnering at HC Wainwright 2020

Join IAG’s Venture Partners and Bio-Partnering Team at HC Wainwright 2020

Dr. Olga Kubassova, IAG’s CEO, and David Chia, IAG’s CCO and Head of Bio-Partnering will virtually attend HC Wainwright  biotech-investor meeting, 14-16 September 2020.

Together with our Venture Partners, IAG  is building a diversified investment portfolio of innovative life science companies at various stages of clinical development.

We co-develop, co-invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.

Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models.

More on our recent partnerships can be found here:

About IAG, Image Analysis Group:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.